KYTHERA Acquires Worldwide Rights to Clinical Compound and Key Intellectual Property for Potential Novel Treatment of Hair Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. AWK
5. TSLA
6. USO
7. GNK
8. ARGX
9. PLUR
10. MU

Go back to KYTHERA Acquires Worldwide Rights to Clinical Compound and Key Intellectual Property for Potential Novel Treatment of Hair Loss

Kythera Biophrarma (KYTH) Enters Hair Loss IP Agreement with Actelion Pharma, Univ. of Pennsylvania

February 10, 2015 4:31 PM EST

Kythera Biophrarma (NASDAQ: KYTH) has entered into separate license agreements with Actelion Pharmaceuticals Ltd. and the University of Pennsylvania for a novel approach for the treatment of hair loss, which together could enable KYTHERA to bring a new treatment to the very large and still highly unsatisfied hair loss market.

"These two licenses build on KYTHERA's focus on developing and commercializing high-value, self-pay aesthetic products that have the promise to yield high patient satisfaction and enhanced self image," said Keith Leonard, KYTHERA's president and CEO. "Based on several years of research and... More